

Anti-F9/F10, Humanized Antibody

rev 11/21

CATALOG NO.: A2250-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a bispecific humanized monoclonal antibody that specifically binds to both Factor IXa and Factor X. Under normal conditions, the presence of thrombin or other coagulation factors causes dissociation of Factor VIII from vWF and enables the formation of activated Factor VIIIa. Activated Factor VIIIa then binds to activated Factor IXa on the phospholipid surface of platelet cells. This complex formation favors the binding of Factor IXa to Factor X and its subsequent conversion to Factor Xa, which later promotes the coagulation process. Hemophilic patients are deficient in Factor VIII/VIIIa and hence have a dysfunctional process of coagulation.

ALTERNATE NAMES: FIX, P19, PTC, HEMB, THPH8, F9 p22, F9, FX, FXA, F10

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG4, kappa

SOURCE: CHO cells

IMMUNOGEN: Human Factor 9/Factor 10

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80 °C. Avoid freeze/thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-IL-6 receptor, Human IgG1 Antibody (A1447)
 Anti-CD20, Chimeric Antibody (A1049)
 Anti-VEGF, Humanized Antibody (A1045)
 Anti-CD19/CD3ε, Bispecific Antibody (A2225)
 Anti-CD20, Humanized Antibody (A2180)

FOR RESEARCH USE ONLY! Not to be used on humans.